Pharmacologic response to depressive disorders among adolescents

Psychiatric Services

Volumn 56, Issue 9, 2005, Pages 1089-1097

  Sewitch, Maida J ^a   Blais, Régis ^b   Rahme, Elham ^a   Bexton, Brian ^c   Galarneau, Sophie ^b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; LITHIUM CARBONATE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADJUSTMENT DISORDER; ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; CANADA; CHILD; CHILD PSYCHIATRY; DEPRESSION; DRUG INDICATION; DRUG RESPONSE; DRUG USE; DYSTHYMIA; FEMALE; GENDER; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PEDIATRICIAN; POPULATION RESEARCH; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; RISK; RURAL AREA; SOCIAL WELFARE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; PEDIATRICS; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; PSYCHIATRY; PSYCHOTROPIC DRUGS; QUEBEC; RETROSPECTIVE STUDIES; RISK; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; SOCIOECONOMIC FACTORS; SUICIDE;

EID: 24644490041     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.56.9.1089     Document Type: Article

References (60)

1. Lewinsohn PM, Rohde P, Seeley JR: Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clinical Psychology Review 18: 765-794, 1998
2. Kessler RC, Avenevoli S, Merikangas KR: Mood disorders in children and adolescents: an epidemiologic perspective. Biological Psychiatry 49:1002-1014, 2001
3. Weller EB, Weller RA: Depression in adolescents: growing pains or true morbidity? Journal of Affective Disorders 61:S9-S13, 2001
4. Parker G, Roy K: Adolescent depression: a review. Australian and New Zealand Journal of Psychiatry 35:572-580, 2000
5. Weller EB, Weller RA: The serious nature of teenage "blues." Journal of Affective Disorders 61:S1, 2000
6. American Academy of Child and Adolescent Psychiatry Official Action: practice parameters for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry 37:63S-83S, 1998
7. Simantov E, Schoen C, Klein JD: Health-compromising behaviors: why do adolescents smoke or drink? Identifying underlying risk and protective factors. Archives of Pediatric and Adolescent Medicine 154: 1025-1033, 2000
8. Glied S, Pine DS: Consequences and correlates of adolescent depression. Archives of Pediatric and Adolescent Medicine 156:1009-1014, 2002
9. DeBar LL, Clarke GN, O'Connor E, et al: Treated prevalence, incidence, and pharmacotherapy of child and adolescent mood disorders in an HMO. Mental Health Services Research 3:73-89, 2001
10. Lewinsohn PM, Rohde P, Klein DN, et al: Natural course of adolescent major depressive disorder: I. continuity into young adulthood. Journal of the American Academy of Child and Adolescent Psychiatry 38:58-63, 1999
11. Reinherz HZ, Paradis AD, Giaconia RM, et al: Childhood and adolescent predictors of major depression in the transition to adulthood. American Journal of Psychiatry 160:2141-2147, 2003
12. Pine DS, Cohen E, Cohen P, et al: Adolescent depressive symptoms as predictors of adult depression: moodiness or mood disorder? American Journal of Psychiatry 156: 133-135, 1999
13. Martin A, Cohen DJ: Adolescent depression: window of (missed?) opportunity. American Journal of Psychiatry 157:1549-1551, 2000
14. Lewinsohn PM, Rohde P, Seeley JR, et al: Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. American Journal of Psychiatry 157:1584-1591, 2000
15. Canals J, Domenech-Llaberia E, Fernandez-Ballart J, et al: Predictors of depression at eighteen: a 7-year follow-up study in a Spanish nonclinical population. European Child and Adolescent Psychiatry 11:226-233, 2002
16. Lewinsohn PM, Rohde P, Seeley JR: Treatment of adolescent depression: frequency of services and impact on functioning in young adulthood. Depression and Anxiety 7:47-52, 1998
17. Kung H-C, Pearson JL, Liu X: Risk factors for male and female suicide decedents ages 15-64 in the United States: results from the 1993 National Mortality Followback Survey. Social Psychiatry and Psychiatric Epidemiology 38:419-426, 2003
18. Thorpe L, Whitney DK, Kutcher SP, et al: Clinical guidelines for the treatment of depressive disorders: VI. special populations. Canadian Journal of Psychiatry 46:63S-76S, 2001
19. Park RJ, Goodyer IM: Clinical guidelines for depressive disorders in childhood and adolescence. European Child and Adolescent Psychiatry 9:147-161
20. Culpepper L, Davidson JRT, Dietrich AJ, et al: Suicidality as a possible side effect of antidepressant treatment. Journal of Clinical Psychiatry 65:742-749, 2004
21. Vitiello B, Swedo S: Antidepressant medications in children. New England Journal of Medicine 350:1489-1491, 2004
22. Wessely S, Kerwin R: Suicide risk and the SSRIs. JAMA 292:379-381, 2004
23. TADS Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 292: 807-820, 2004
24. Harris G: FDA toughens warning on antidepressant drugs. New York Times, Oct 16 2004
25. Gray D, Achilles J, Keller T, et al: Utah youth suicide study, phase I: government agency contact before death. Journal of the American Academy of Child and Adolescent Psychiatry 41:427-434, 2002
26. Weller EB, Weller RA: Treatment options in the management of adolescent depression. Journal of Affective Disorders 61: S23-S28, 2000
27. Geller B, Reising D, Leonard HL, et al: Critical review of tricyclic antidepressant use in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 38:513-516, 1999
28. Ambrosini PJ: A review of pharmacotherapy of major depression in children and adolescents. Psychiatric Services 51:627-633, 2000
29. Martin A, Leslie D: Trends in psychotropic medication costs for children and adolescents, 1997-2000. Archives of Pediatric and Adolescent Medicine 157:997-1004, 2003
30. Kairuz T, Truter I, Hugo J, et al: Prescribing patterns of tricyclic and selective serotonin reuptake inhibitor antidepressants among a sample of adolescents and young adults. Pharmacoepidemiology and Drug Safety 12:379-382, 2003
31. Pietraru C, Barbui C, Poggio L, et al: Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. European Journal of Clinical Pharmacology 57:605-609, 2001
32. Olfson M, Marcus SC, Weissman MM, et al: National trends in the use of psychotropic medications by children. Journal of the American Academy of Child and Adolescent Psychiatry 41:514-521, 2002
33. Zito JM, Safer DJ: Services and prevention: pharmacoepidemiology of antidepressant use. Biological Psychiatry 49:1121-1127, 2001
34. Cuffe SP, Waller JL, Cuccaro ML, et al: Race and gender differences in the treatment of psychiatric disorders in young adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 34: 1536-1543, 1995
35. Efron D, Hiscock H, Sewell JR, et al: Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 111:372-375
36. Jensen PS, Bhatara VS, Vitiello B, et al: Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. Journal of the American Academy of Child and Adolescent Psychiatry 38:557-565, 1999
37. Olfson M, Gameroff MJ, Marcus SC, et al: Outpatient treatment of child and adolescent depression in the United States. Archives of General Psychiatry 60:1236-1242, 2003
38. Tamblyn R, Lavoie G, Petrella L, et al: The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. Journal of Clinical Epidemiology 48:999-1009, 1995
39. International Classification of Diseases, Ninth Revision. Geneva, World Health Organization, 1975
40. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994
41. SAS Institute Inc: SAS Version 8.02, Cary, NC, 2001
42. Liang K-Y, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 73:13-22, 1986
43. The GENMOD Procedure in SAS/STAT Software: Changes and Enhancements for Release 6.12. Cary, NC, SAS Institute, 1996
44. Akaike H: A new look at statistical model identification. Institute of Electrical and Electronics Engineers Transactions on Automatic Control AC-19:716-723, 1974
45. Ge X, Conger RD, Elder GH Jr: Pubertal transition, stressful life events, and the emergence of gender differences in adolescent depressive symptoms. Developmental Psychology 37:404-417, 2001
46. Reinecke MA, Ryan NE, DuBois DL: Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry 31:26-34, 1998
47. Brent DA, Holder D, Kolko D: A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Archives of General Psychiatry 54:877-885, 1997
48. La Régie de l'assurance maladie du Québec: Nombre de prestataires d'assistance-emploi selon le sexe, le groupe d'âge et la région sociosanitire. [Number of Beneficiaries Receiving Employment Assistance According to Sex, Age, and Sociosanitary Region.]. Québec, 2001
49. La Régie de l'assurance maladie du Québec. Nombre d'adhérents selon le sexe, le groupe d'âge et la région sociosanitire de la personne assurée, régime d'assurance médicaments, Québec, 2001
50. La Régie de l'assurance maladie du Québec. Nombre de personnes inscrites et admissibles au régime d'assurance maladie du Québec selon le sexe, le groupe d'âge et la région sociosanitire, Québec, 2001
51. Rushton JL, Clark SJ, Freed GL: Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Pediatrics 105:E82, 2000
52. Pampalon R, Raymond G: A deprivation index for health and welfare planning in Quebec. Chronic Diseases in Canada 21:113-122, 2000
53. Comité de revue de l'utilisation des medicaments [Committee for Review of the Use of Medications]: Étude sur les stimulants utilisés dans le traitement du trouble de déficit de l'attention/hyperactivité [Study on the Stimulants Used to Treat Attention Deficit Disorder/Hyperactivity]. Sillery, Quebec, 2001
54. Abbott A: British panel bans use of antidepressant to treat children. Nature 423:792, 2003
55. Waechter F: Paroxetine must not be given to patients under 18. British Medical Journal 326:1282, 2003
56. Wooltorton E: Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients. Canadian Medical Association Journal 169:446, 2003
57. Varley CK: Psychopharmacological treatment of major depressive disorder in children and adolescents. JAMA 290:1091-1093, 2003
58. Health Canada and Health Products and Food Branch: Discontinuation of sales of nefazodone in Canada. Available at www. hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ bms_nefaz odone_2_hpc_e.pdf, 2003
59. Harris G: Study finds less youth antidepressant use. The New York Times, Business, 2004
60. Brent D: Antidepressants and pediatric depression: the risk of doing nothing. New England Journal of Medicine 351:1598-1601, 2004